Grifols logo

Grifols

GRFS | NASDAQ
Chart Builder DCF Calculator
$8.73
+$0.04 (+0.46%)
At close: Nov 16, 2026, 4:00 PM ET
$8.73
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET
+0.46%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
60.9
Fundamentals Strong
Market Sentiment Neutral
Moat Narrow
Sector Rank #127/1021 (Top 12%)

Key Statistics

Market Data

Market Cap $7.39B
1D Range
8.65 8.79
52W Range
7.02 9.72

Valuation (TTM)

PE 11.17
PB 1.13
EV/EBITDA 8.73

Valuation (NTM)

Forward PE 9.07
Forward PEG 0.81
Price Target $9.00
Loading financial charts...

Profile

Grifols, S.A., a company founded in 1940 and headquartered in Barcelona, Spain, specializes in the development, manufacture, and distribution of therapeutic products, with a primary focus on those der...

Sector Healthcare
Employees 25,258
IPO Date Jun 2, 2011
Fiscal Year January - December

Latest News

Grifols: Plasma, Profits, And Recovery Gathering Momentum

14 days ago · seekingalpha.com

Grifols: Plasma, Profits, And Recovery Gathering Momentum
Grifols, S.A. (GIKLY) Q3 2026 Earnings Call Transcript

14 days ago · seekingalpha.com

Grifols, S.A. (GIKLY) Q3 2026 Earnings Call Transcript
Grifols Q3 Earnings Call Highlights

14 days ago · marketbeat.com

Grifols Q3 Earnings Call Highlights

2 months ago · zacks.com

GRFS vs. SDZNY: Which Stock Should Value Investors Buy Now?
Grifols says Canada plasma license suspension has no impact

2 months ago · reuters.com

Grifols says Canada plasma license suspension has no impact
Grifols: Better Plasma Economics Can Unlock A Discounted Equity

2 months ago · seekingalpha.com

Grifols: Better Plasma Economics Can Unlock A Discounted Equity
GRFS or SDZNY: Which Is the Better Value Stock Right Now?

2 months ago · zacks.com

GRFS or SDZNY: Which Is the Better Value Stock Right Now?
Grifols Announces Last Patient Last Visit in SPARTA, its Phase 3 Outcomes Study of Prolastin®-C in Patients With Emphysema Due to Alpha-1 Antitrypsin Deficiency

3 months ago · globenewswire.com

Grifols Announces Last Patient Last Visit in SPARTA, its Phase 3 Outcomes Study of Prolastin®-C in Patients With Emphysema Due to Alpha-1 Antitrypsin Deficiency
Grifols, S.A. (GIKLY) Q2 2026 Earnings Call Transcript

4 months ago · seekingalpha.com

Grifols, S.A. (GIKLY) Q2 2026 Earnings Call Transcript
Grifols Q2 Earnings Call Highlights

4 months ago · marketbeat.com

Grifols Q2 Earnings Call Highlights

Earnings

Latest Earnings
Nov 2, 2026
EPS
$0.34
Beat +4.90%
REV
$2.28B
Beat +3.26%
Next Earnings
Mar 4, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
1
Consensus
Hold
Price Target
$9.00
Upside
+3.09%
Buy (0)
Hold (1)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.